View Archive »
About The Cover
Pimi induces cleavage of caspase-3 in G2/M and aneuploid cells but cell death is not blocked by pan-caspase inhibition. Cells co-treated for 48 hours with either DMSO, Pim-ci or Pimi and 20 μM of the pan-caspase inhibitor QVD-OPH were harvested and stained with propidium iodide (PI) and analyzed by FACS as well as cytospun onto glass slides, labeled with cleaved caspase-3 and analyzed by immunofluorescence. See Forshell et al.
|
|
Table of Contents
Editorial
|
| LMTK3 and evolution |
|
https://doi.org/10.18632/oncotarget.291
Justin Stebbing, Aleksandra Filipović, and Georgios Giamas
|
| 428-429 |
|
| Is nanomedicine still promising |
|
https://doi.org/10.18632/oncotarget.295
Pubudu M. Peiris, and Efstathios Karathanasis
|
| 430-432 |
|
| Heat shock proteins and cancer therapy: The trail grows hotter |
|
https://doi.org/10.18632/oncotarget.294
John R. Subjeck, and Elizabeth A. Repasky
|
| 433-434 |
Reviews
|
| Elevated PI3K signaling drives multiple Breast Cancer subtypes |
|
https://doi.org/10.18632/oncotarget.285
Jessica Adams, Nathan F. Schachter, Jeff C. Liu, Eldad Zacksenhaus, and Sean Eoin Egan
|
| 435-447 |
Research Papers
|
| The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Mycinduced Bcell lymphomas |
|
https://doi.org/10.18632/oncotarget.283
Linus Plym Forshell, Yongmei Li, Tacha Zi Plym Forshell, Martina Rudelius, Lisa Nilsson, Ulrich Keller, and Jonas Nilsson
|
| 448-460 |
|
| Strong Inhibition of Xenografted Tumor Growth by LowLevel Doses of [32P]ATP |
|
https://doi.org/10.18632/oncotarget.289
Yulan Cheng, Jian Yang, Rachana Agarwal, Gilbert M. Green, Ron C. Mease, Martin G. Pomper, Stephen J. Meltzer, and John M. Abraham
|
| 461-466 |
|
| Phosphorylation of AKT: a Mutational Analysis |
|
https://doi.org/10.18632/oncotarget.293
Jonathan R. Hart, and Peter K. Vogt
|
| 467-476 |
Research Perspectives
|
| Molecular signature induced by RNASET2 a tumor antagonizing gene in ovarian cancer cells |
|
https://doi.org/10.18632/oncotarget.274
Francesco Acquati, Laura Monti, Marta Lualdi, Marco Fabbri, Maria Grazia Sacco, Laura Gribaldo, and Roberto Taramelli
|
| 477-484 |
|
| Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies |
|
https://doi.org/10.18632/oncotarget.281
Francesco Passamonti, Margherita Maffioli, Domenica Caramazza, and Mario Cazzola
|
| 485-490 |
|
| p21activated kinase 1: PAK’ed with potential |
|
https://doi.org/10.18632/oncotarget.271
Christy Ong, Adrian Jubb, Wei Zhou, Peter Haverty, Adrian Harris, Marcia Belvin, Lori Friedman, Hartmut Koeppen, and Klaus Hoeflich
|
| 491-496 |
|
| RIP KinaseMediated Necrosis as an Alternative Mechanisms of Photoreceptor Death |
|
https://doi.org/10.18632/oncotarget.286
Yusuke Murakami, Joan W. Miller, and Demetrios G. Vavvas
|
| 497-509 |
|
| Targeting mTOR for the treatment of AML New agents and new directions |
|
https://doi.org/10.18632/oncotarget.290
Jessica K. Altman, Antonella Sassano, and Leonidas C. Platanias
|
| 510-517 |
|
| A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation |
|
https://doi.org/10.18632/oncotarget.296
Erik A. Nelson, Sreenath V. Sharma, Jeffrey Settleman, and David A. Frank
|
| 518-524 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
